Background. Nipah belongs to the genus Henipavirus and the Paramyxoviridae family. It is an endemic most commonly found at South Asia and has first emerged in Malaysia in 1998. Bats are found to be the main reservoir for this virus, causing disease in both humans and animals. The last outbreak has occurred in May 2018 in Kerala. It is characterized by high pathogenicity and fatality rates which varies from 40% to 70% depending on the severity of the disease and on the availability of adequate healthcare facilities. Currently, there are no antiviral drugs available for NiV disease and the treatment is just supportive. Clinical presentations for this virus range from asymptomatic infection to fatal encephalitis. Objective. This study is aimed at predicting an effective epitope-based vaccine against glycoprotein G of Nipah henipavirus, using immunoinformatics approaches. Methods and Materials. Glycoprotein G of the Nipah virus sequence was retrieved from NCBI. Different prediction tools were used to analyze the epitopes, namely, BepiPred-2.0: Sequential B Cell Epitope Predictor for B cell and T cell MHC classes II and I. Then, the proposed peptides were docked using Autodock 4.0 software program. Results and Conclusions. The two peptides TVYHCSAVY and FLIDRINWI have showed a very strong binding affinity to MHC class I and MHC class II alleles. Furthermore, considering the conservancy, the affinity, and the population coverage, the peptide FLIDRINWIT is highly suitable to be utilized to formulate a new vaccine against glycoprotein G of Nipah henipavirus. An in vivo study for the proposed peptides is also highly recommended.

中文翻译：

---

使用免疫信息学方法针对尼帕亨尼帕病毒糖蛋白 G 的基于表位的肽疫苗。

背景。尼帕属于亨尼帕病毒属和副粘病毒科。它是南亚最常见的地方病，1998 年首次出现在马来西亚。蝙蝠被发现是这种病毒的主要宿主，会导致人类和动物患病。上一次爆发发生在 2018 年 5 月的喀拉拉邦。它的特点是高致病率和致死率，根据疾病的严重程度和足够的医疗保健设施的可用性，从 40% 到 70% 不等。目前，没有可用于 NiV 疾病的抗病毒药物，治疗只是支持性的。这种病毒的临床表现从无症状感染到致命性脑炎不等。客观的. 本研究旨在使用免疫信息学方法预测针对尼帕亨尼帕病毒糖蛋白 G 的有效表位疫苗。方法和材料。Nipah 病毒序列的糖蛋白 G 取自 NCBI。使用不同的预测工具来分析表位，即 BepiPred-2.0：Sequential B Cell Epitope Predictor for B 细胞和 T 细胞 MHC II 类和 I 类。然后，使用 Autodock 4.0 软件程序对接提出的肽。结果和结论. TVYHCSAVY 和 FLIDRINWI 这两种肽对 MHC I 类和 MHC II 类等位基因显示出非常强的结合亲和力。此外，考虑到保守性、亲和力和种群覆盖率，肽FLIDRINWIT非常适合用于制备针对尼帕亨尼帕病毒糖蛋白G的新疫苗。还强烈建议对提议的肽进行体内研究。